Palisade Bio, Inc. (PALI)

Palisade Bio Statistics

Total Valuation

Palisade Bio has a market cap or net worth of $350.16 million. The enterprise value is $345.14 million.

Market Cap	350.16M
Enterprise Value	345.14M

Important Dates

The last earnings date was Monday, November 10, 2025, after market close.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Palisade Bio has 149.00 million shares outstanding. The number of shares has increased by 367.35% in one year.

Current Share Class	149.00M
Shares Outstanding	149.00M
Shares Change (YoY)	+367.35%
Shares Change (QoQ)	+55.80%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	29.00%
Float	102.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	6.68
P/TBV Ratio	109.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.07.

Current Ratio	1.96
Quick Ratio	1.51
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,041.55

Financial Efficiency

Return on equity (ROE) is -228.64% and return on invested capital (ROIC) is -137.86%.

Return on Equity (ROE)	-228.64%
Return on Assets (ROA)	-87.81%
Return on Invested Capital (ROIC)	-137.86%
Return on Capital Employed (ROCE)	-327.81%
Revenue Per Employee	n/a
Profits Per Employee	-$1.40M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +38.24% in the last 52 weeks. The beta is 1.62, so Palisade Bio's price volatility has been higher than the market average.

Beta (5Y)	1.62
52-Week Price Change	+38.24%
50-Day Moving Average	1.96
200-Day Moving Average	1.12
Relative Strength Index (RSI)	60.52
Average Volume (20 Days)	5,859,198

Short Selling Information

The latest short interest is 12.82 million, so 8.60% of the outstanding shares have been sold short.

Short Interest	12.82M
Short Previous Month	13.98M
Short % of Shares Out	8.60%
Short % of Float	12.54%
Short Ratio (days to cover)	2.62

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-11.46M
Pretax Income	-11.23M
Net Income	-11.23M
EBITDA	-11.45M
EBIT	-11.46M
Earnings Per Share (EPS)	-$2.33

Balance Sheet

The company has $5.23 million in cash and $211,000 in debt, giving a net cash position of $5.02 million or $0.03 per share.

Cash & Cash Equivalents	5.23M
Total Debt	211,000
Net Cash	5.02M
Net Cash Per Share	$0.03
Equity (Book Value)	3.21M
Book Value Per Share	0.35
Working Capital	3.35M

Cash Flow

Operating Cash Flow	-10.08M
Capital Expenditures	n/a
Free Cash Flow	-10.08M
FCF Per Share	-$0.07

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Palisade Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-367.35%
Shareholder Yield	-367.35%
Earnings Yield	-3.21%
FCF Yield	-2.88%

Analyst Forecast

The average price target for Palisade Bio is $17.67, which is 651.92% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.67
Price Target Difference	651.92%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.

Last Split Date	Apr 8, 2024
Split Type	Reverse
Split Ratio	1:15

Scores

Altman Z-Score	n/a
Piotroski F-Score	1